Vyome vs RedHill Biopharma
HIND and RDHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and RDHL compare
Vyome grew revenue faster over the last twelve months (−55.6% versus −96.4% for RedHill Biopharma).
Vyome scores higher on the StockData Score (1 against 0 for RedHill Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | RDHL |
|---|---|---|
| Size and price | ||
| Market cap | $11.1M | – |
| Share price | $1.58 | $0.375 |
| Change, 1 year | −70.3% | −65.0% |
| Change, 5 years | −100.0% | −100.0% |
| Beta (5Y) | 1.56 | 1.71 |
| Employees | 18 | 13 |
| StockData Score | ||
| Total score | 1 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 72.4× | – |
| Growth | ||
| Revenue growth (TTM) | −55.6% (better) | −96.4% |
| Revenue growth, 5Y average | −51.0% (better) | −66.2% |
| Profitability | ||
| Gross margin | 50.4% | – |
| Operating margin | −2854% | −2777% (better) |
| Net margin | −2456% | – |
| FCF margin | – | −3376% |
| Return on equity | −149% | – |
| Financial health | ||
| Interest coverage | −229.3× | −5.5× (better) |
| Current ratio | 3.68 (better) | 0.34 |
| Altman Z-score | −12.31 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Buyback yield | −53.1% | – |
| Shareholder yield | −53.1% | – |
| Ownership | ||
| Held by institutions | 2.0% | 0.00% |
| Held by insiders | 6.8% | 4.4% |
| Insider net buying, 12 months | – | −$1.4K |
| Short interest, % of float | 0.28% | – |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- RDHL stock overview
- RDHL income statement
- RDHL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.